IRVINE, Calif.–(BUSINESS WIRE)–JenaValve Technology, Inc., a developer, manufacturer and marketer of differentiated transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, today announced successful patient enrollment in the CE Mark study of the next generation JenaValve […]